Impact of consolidation chemotherapy after concurrent chemoradiation in locally advanced cervical cancer — a randomized controlled trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate the efficacy and safety of consolidation chemotherapy following concurrent chemoradiation in locally advanced cervical cancer.
A randomized controlled trial with 100 patients diagnosed with FIGO 2021 stages IIB–IVA cervical cancer at Mansoura University.
Participants were divided into two arms: one receiving weekly cisplatin-based CCRT followed by 3 cycles of paclitaxel/carboplatin and the control arm receiving standard CCRT.
Tumor responses were assessed with magnetic resonance imaging and RECIST 1.1; toxicities were evaluated by CTCAE v4.0.
Complete response (CR) rates at 9, 12, and 18 months were significantly higher in the treatment group (91.3%, 89.1%, 82.6%) compared to the control (75.5%, 55.1%, 38%) with p-values ranging from 0.004 to ≤0.001.
Disease progression rates were 21.7% in the study group versus 40% in controls, with time to progression longer in the study group (18.3 months vs. 15.0 months; p = 0.006).
Toxicities were manageable with no significant safety concerns.

We only have this paper's title and publication details.

Randomized trial compares long-term tumor response in locally advanced cervical cancer, suggesting benefits of consolidation chemotherapy.

No takes yet. Share an insight, caveat, or question.

Elghamery et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share